Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19067863 | Phage Composition and Its Use in Strengthening Soil Carbon Fixation | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 18770056 | POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASES | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18749700 | COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUS | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18749697 | COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUS | June 2024 | October 2025 | Allow | 16 | 1 | 1 | No | No |
| 18743581 | SMALLPOX VACCINE FOR CANCER TREATMENT | June 2024 | January 2026 | Allow | 20 | 2 | 1 | No | No |
| 18670296 | ONCOLYTIC VIRUS STRAIN | May 2024 | December 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18634012 | ADJUVANT AND VACCINE CONTAINING ADJUVANT | April 2024 | February 2026 | Abandon | 22 | 2 | 1 | No | No |
| 18609504 | HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS | March 2024 | October 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18597018 | Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof | March 2024 | June 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18441086 | SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19) | February 2024 | May 2025 | Allow | 15 | 1 | 0 | No | No |
| 18437608 | CONTRACEPTIVE VACCINE BASED ON THE SPERM-ASSOCIATED PROTEIN CATSPER | February 2024 | March 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18406869 | Novel Adjuvant Compositions | January 2024 | September 2025 | Allow | 20 | 1 | 1 | No | No |
| 18386007 | APPARATUS FOR DETERMINING ADMINISTRATION FORM OF A COMPOSITION OF AN ENGINEERED VIRUS-BASED NANOPARTICLE FOR A TREATMENT OF AN AUTOIMMUNE CONDITION | November 2023 | September 2025 | Allow | 22 | 4 | 1 | Yes | No |
| 18491193 | STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | October 2023 | September 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18462133 | MODIFIED ONCOLYTIC VIRUS | September 2023 | July 2025 | Allow | 22 | 1 | 1 | No | No |
| 18458903 | CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE | August 2023 | May 2025 | Allow | 21 | 2 | 0 | No | No |
| 18238829 | SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY | August 2023 | July 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18450908 | ADJUVANT FOR ANIMAL AND HUMAN VACCINES | August 2023 | September 2025 | Allow | 25 | 1 | 1 | No | No |
| 18447439 | IL-36 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | August 2023 | September 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18365671 | NOVEL VACCINE ADJUVANT | August 2023 | April 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18365082 | RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED NA | August 2023 | January 2025 | Allow | 18 | 0 | 1 | Yes | No |
| 18332291 | Ebola Virus Antibodies and Binding Agents Derived Therefrom | June 2023 | February 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18307593 | ONCOLYTIC VIRUSES AS ADJUVANTS | April 2023 | July 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18191625 | IMMUNO-MODULATED REPLICATION-EFFICIENT VACCINIA VIRUS STRAIN | March 2023 | January 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18187133 | IDENTIFICATION OF VARIABLE INFLUENZA RESIDUES AND USES THEREOF | March 2023 | January 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18181754 | HPV VACCINE | March 2023 | April 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18163837 | ENGINEERED VIRUS | February 2023 | April 2025 | Allow | 26 | 6 | 0 | Yes | No |
| 18163038 | Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens | February 2023 | March 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18161210 | REMOVAL OF AGGLOMERATES | January 2023 | September 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18010412 | SWINE INFLUENZA A VIRUS VACCINE COMPRISING TWO DISTINCT RNA REPLICON PARTICLES | December 2022 | January 2026 | Allow | 37 | 2 | 0 | Yes | No |
| 17993182 | TUMOR-SELECTIVE E1A AND E1B MUTANTS | November 2022 | September 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17922670 | Coronavirus Assays, Diagnostic Methods, Treatment Methods, and Compositions Related Thereto | November 2022 | October 2025 | Allow | 36 | 0 | 0 | No | No |
| 18050806 | THERAPEUTIC AND PREVENTATIVE CANCER VACCINES | October 2022 | November 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17799464 | HPV VACCINE | August 2022 | March 2026 | Allow | 43 | 1 | 1 | No | No |
| 17798189 | Vaccine and Methods for Detecting and Preventing Filariasis | August 2022 | July 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17817245 | MODIFIED ONCOLYTIC VIRUS | August 2022 | October 2024 | Allow | 27 | 5 | 1 | Yes | No |
| 17811059 | VIRUS PURIFICATION | July 2022 | September 2024 | Allow | 26 | 2 | 1 | No | No |
| 17788671 | POLYMERIC NANOPARTICLES FOR ENHANCED CANCER TREATMENT | June 2022 | February 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17846817 | REPLICATION-DEFECTIVE ARENAVIRUS VECTORS | June 2022 | October 2024 | Allow | 28 | 1 | 1 | No | No |
| 17787560 | NOVEL PRIME-BOOST INFLUENZA VACCINE | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17784838 | MULTIVALENT HVT VECTOR VACCINE | June 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17748715 | SARS-CoV-2 POLYPEPTIDES | May 2022 | February 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17775475 | METHOD FOR PRODUCING REASSORTANT INFLUENZA VIRUSES | May 2022 | November 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17607118 | LIVE IMAGING SYSTEM TO VISUALIZE THE RETRO-TRANSCRIBED VIRAL DNA GENOME | April 2022 | December 2025 | Allow | 50 | 1 | 1 | No | No |
| 17726952 | Immunogenic Compositions Against SARS-COV-2 Variants and Their Methods of Use | April 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17767291 | DNA VACCINE CAPABLE OF EFFECTIVELY TREATING AND/OR PREVENTING TYPE 1 DIABETES AND USE THEREOF | April 2022 | December 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17713718 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | April 2022 | January 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17709009 | COMBINATION GMCI AND ATRI CANCER TREATMENT | March 2022 | January 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17754280 | tFIBER PROTEIN FRAGMENT OF AVIAN EGG DROP SYNDROME VIRUS AND VACCINE COMPOSITION PREPARED THEREOF, PREPARATION METHOD AND USE | March 2022 | August 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17764295 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | March 2022 | October 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17761403 | PRODUCTION AND FUNCTIONALIZATION OF NANOPARTICLES DERIVED FROM PHAGE T5 AND THERAPEUTIC USES | March 2022 | October 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17642756 | MODIFIED VESICULAR STOMATITIS VIRUS GLYCOPROTEIN AND USES THEREOF FOR THE TREATMENT OF BRAIN TUMORS | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17639773 | SEASONAL INFLUENZA VACCINE CAPABLE OF INDUCING VIRUS-SPECIFIC ANTIBODY INTO NASAL CAVITY | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17684269 | ANTIVIRAL VACCINES USING SPHERICAL NUCLEIC ACIDS | March 2022 | March 2026 | Allow | 49 | 1 | 1 | No | No |
| 17675535 | INFLUENZA VACCINE COMPOSITION BASED ON NOVEL NUCLEIC ACID | February 2022 | September 2025 | Allow | 43 | 1 | 2 | No | No |
| 17629356 | MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINS | January 2022 | November 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17579459 | Polyvalent immunogenicity composition for human papillomavirus | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17626340 | METHOD FOR VACCINATING AVIANS AGAINST REOVIRUS | January 2022 | October 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17626337 | SENECAVIRUS A VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM | January 2022 | October 2025 | Allow | 45 | 2 | 1 | No | No |
| 17621816 | INFLUENZA VIRUS NEURAMINIDASE AND USES THEREOF | December 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17618283 | MUCOSAL VACCINE FORMULATIONS | December 2021 | October 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17617258 | INFLUENZA VIRUS BACKBONE | December 2021 | March 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17616006 | AAV VECTORS WITH MYELIN PROTEIN ZERO PROMOTER AND USES THEREOF FOR TREATING SCHWANN CELL-ASSOCIATED DISEASES LIKE CHARCOT-MARIE-TOOTH DISEASE | December 2021 | November 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17541134 | ANTIVIRAL IMMUNOTHERAPY BY MEMBRANE RECEPTOR LIGATION | December 2021 | January 2026 | Allow | 49 | 5 | 1 | Yes | No |
| 17607495 | COMPOSITIONS FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | October 2021 | September 2025 | Allow | 47 | 1 | 0 | No | No |
| 17600164 | IMMUNE-STIMULATORY COMPOSITIONS AND USE THEREOF | September 2021 | February 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17440546 | METHOD OF MODULATING MUCOSAL IMMUNOGENICITY | September 2021 | January 2026 | Allow | 52 | 2 | 1 | No | No |
| 17434180 | NOVEL PLANT GROWTH PROMOTING MICROBIAL COMPOSITIONS | August 2021 | January 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17443261 | PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY | July 2021 | December 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17423849 | PHLIP®-MEDIATED INTRACELLULAR DELIVERY OF IMMUNO-STIMULATORY COMPOUNDS | July 2021 | April 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17422641 | CD200AR LIGANDS FOR CANCER IMMUNOTHERAPY | July 2021 | May 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17368994 | VIRAL PREPARATIONS AND METHODS FOR TREATING AND MODULATING MITOCHONDRIAL EFFECTS OF CORONAVIRUS INFECTIONS. | July 2021 | December 2024 | Allow | 41 | 5 | 1 | Yes | No |
| 17414156 | SERUM FREE INTRACELLULAR PATHOGEN VACCINE | June 2021 | October 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17413512 | MEMBRANE BOUND IL12 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17334417 | CAR-T CELLS WITH HUMANIZED CD19 SCFV WITH MUTATION IN CDR 1 REGION | May 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17297353 | BIOMARKERS FOR CD47 BLOCKADE THERAPY | May 2021 | February 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17295287 | COMPOSITIONS AND METHODS FOR INTERNAL CONTROLS OF MICROVESICLE ISOLATIONS | May 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17275253 | IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE AND APPLICATION THEREOF | May 2021 | November 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17307066 | MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONAVIRUSES | May 2021 | November 2024 | Allow | 42 | 3 | 0 | Yes | No |
| 17288019 | MODIFIED PDC LINE FOR SECRETING A CYTOKINE | April 2021 | December 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17287429 | SYNP57 (PROA14), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PHOTORECEPTORS | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17232597 | NOVEL CANCER ANTIGENS AND METHODS | April 2021 | November 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17285874 | MODIFIED CMV GB PROTEIN AND CMV VACCINE INCLUDING SAME | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17282673 | METHODS FOR MEASURING THE TITER AND POTENCY OF VIRAL VECTOR PARTICLES | April 2021 | April 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17282172 | COMPOSITION FOR PREVENTING OR TREATING BENIGN TUMOR | April 2021 | June 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17181657 | SINDBIS CONTROL VIRUS | February 2021 | February 2025 | Allow | 48 | 5 | 1 | Yes | No |
| 17265498 | COMPOSITIONS COMPRISING ANNEXIN V AND HPV TUMOR ANTIGEN FUSION POLYPEPTIDES AND METHODS FOR MAKING AND USE | February 2021 | November 2025 | Allow | 57 | 2 | 1 | Yes | Yes |
| 17263049 | TREATMENT OF MUCOPOLYSACCHARIDOSIS IVA | January 2021 | November 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17151840 | PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS | January 2021 | February 2025 | Allow | 49 | 4 | 1 | Yes | Yes |
| 17259849 | METHODS OF TREATING CANCER WITH TNF EXPRESSING MYXOMA VIRUS | January 2021 | November 2024 | Allow | 46 | 1 | 1 | No | No |
| 17253927 | ONCOLYTIC VIRUS OR ANTIGEN PRESENTING CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40-LIGAND | December 2020 | October 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 17252123 | VACCINE VECTOR ENCODING MUTATED GNAQ FOR TREATMENT OF UVEAL MELANOMA AND CANCERS HAVING ONCOGENIC MUTATIONS ON GNAQ AND GNA11 PROTEINS | December 2020 | April 2025 | Abandon | 52 | 2 | 1 | Yes | No |
| 17116538 | METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS | December 2020 | January 2025 | Abandon | 50 | 0 | 2 | Yes | No |
| 17056306 | ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORM | November 2020 | April 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 17044074 | RECOMBINANT ONCOLYTIC VIRUS COMPOSITION AND USE THEREOF | September 2020 | March 2025 | Allow | 53 | 4 | 0 | Yes | No |
| 17042822 | PERSONALIZED CANCER VACCINES | September 2020 | January 2025 | Allow | 52 | 1 | 1 | No | No |
| 16975298 | PREVENTION OR TREATMENT OF CARDIAC ARRHYTMIA AND SUDDEN CARDIAC DEATH | August 2020 | December 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16626019 | RECOMBINANT ONCOLYTIC VIRUSES FOR TREATMENT OF METASTATIC CANCERS | December 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16307710 | METHOD FOR THE DETECTION OF AN IGM ANTIBODY SPECIFIC FOR A FLAVIVIRUS IN A SAMPLE | December 2018 | November 2019 | Allow | 12 | 2 | 0 | No | No |
| 16176461 | USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR | October 2018 | March 2020 | Allow | 17 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, BAO Q.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LI, BAO Q works in Art Unit 1671 and has examined 302 patent applications in our dataset. With an allowance rate of 97.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner LI, BAO Q's allowance rate of 97.7% places them in the 89% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by LI, BAO Q receive 2.05 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LI, BAO Q is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +1.3% benefit to allowance rate for applications examined by LI, BAO Q. This interview benefit is in the 20% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 32.5% of applications are subsequently allowed. This success rate is in the 69% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 61.1% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 97.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 84.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 24.5% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.